Evidence Regarding Pharmacogenetics in Pain Management and Cancer

D Max Smith; William D Figg

doi:10.1093/oncolo/oyac277

Evidence Regarding Pharmacogenetics in Pain Management and Cancer

Oncologist. 2023 Mar 17;28(3):189-192. doi: 10.1093/oncolo/oyac277.

Authors

D Max Smith^{1

2}, William D Figg³

Affiliations

¹ MedStar Genetic Medicine, MedStar Health, Columbia, MD, USA.
² Department of Oncology, Georgetown University Medical Center, Washington, DC, USA.
³ Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Abstract

Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics. This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.

Keywords: cancer pain; opioids; pain; pharmacogenetics; pharmacogenomics.

Publication types

Comment

MeSH terms

Analgesics, Opioid / therapeutic use
Cancer Pain* / drug therapy
Cancer Pain* / genetics
Catechol O-Methyltransferase / genetics
Catechol O-Methyltransferase / therapeutic use
Cytochrome P-450 CYP2D6 / genetics
Cytochrome P-450 CYP2D6 / therapeutic use
Genotype
Humans
Morphine / therapeutic use
Neoplasms* / drug therapy
Neoplasms* / genetics
Oxycodone / therapeutic use
Pain Management
Pharmacogenetics

Substances

Oxycodone
Morphine
Analgesics, Opioid
Catechol O-Methyltransferase
Cytochrome P-450 CYP2D6